Brief Review of Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia— Santos 2020

This is a brief audio review. In the article Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia published, 2020 by Santos and Colleagues, The outcomes and key points are as noted: Evolocumab reduced low density lipoprotein levels in pediatric patients with hypercholesterolemia. At 6 months, reduction in low density lipoprotein was more effective in the evolocumab group versus the placebo group, mean difference -38.3 percentage points, P<0.001. This was a Randomized controlled trial, double blinded with 157 patients who were Patients between the ages of 10 years old and 17 years old, who have a history of lipid lowering agent therapy at a stable dose for a minimum of 4 weeks, with a low density lipoprotein level of 130 milligrams per deciliter or greater and a triglyceride level of 400 milligram per deciliter or less.

Santos RD, Ruzza A, Hovingh GK, Wiegman A, Mach F, Kurtz CE, Hamer A, Bridges I, Bartuli A, Bergeron J, Szamosi T, Santra S, Stefanutti C, Descamps OS, Greber-Platzer S, Luirink I, Kastelein JJP, Gaudet D; HAUSER-RCT Investigators. Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia. N Engl J Med. 2020 Oct 1;383(14):1317-1327. doi: 10.1056/NEJMoa2019910. Epub 2020 Aug 29. PMID: 32865373.